Drug Trial Radar · NCT05605496
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
57
Actual
Start
Jan 6, 2023
Primary completion
Jan 1, 2027
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Centre Leon BerardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NETRIS Pharma
- First posted
- Nov 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic solid tumors with various sensitivity to anti-PD-1/PD-L1: * Cohort 1 \[Stable Disease\]: Patients with a radiological documentation of SD according to RECIST V1.1 criteria following at least 12 weeks under standard anti PD-1/PD-L1 therapy. Note: This treatment arm closed on 27/09/2024 due to non-feasibility. * Cohort 2 \[primary refractory\]: Patients with documented radiological PD or short-term SD (\< 6months) according to RECIST V1.1 but with clinical benefit under PD-1/PD-L1 standard therapy. * Cohort 3 \[secondary refractory\]: Patients with documented radiological PD following an initial Objective Response or long-term SD (i.e. ≥6 months) according to RECIST V1.1, with clinical benefit under standard PD-1/PD-L1.
Conditions
- Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
NP137Drug
IV infusion, 14mg/kg, Q3W
anti-PD-1/PD-L1Drug
IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR-12W)Time frame: 12 weeks
- Progression Free Rate at 12 weeks (PFR-12W)Time frame: 12 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Centre Léon Bérard
Lyon, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Institut de Cancérologie Strasbourg Europe (ICANS)
Strasbourg, France
Institut Claudius Regaud (IUCT Oncopole)
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.